GH Research soars as depression treatment succeeds in study

GH Research

06/12/2021 18:18

** Shares of drug developer  GHRS.O  jump 18.4% to $22.8,
snapping a three-day losing streak
    ** GHRS says its lead drug candidate, GH001, met the main
goal in a mid-stage trial, with 7 of 8 patients with
treatment-resistant depression attaining remission by the
seventh day  urn:newsml:reuters.com:*:nGNXqSQ6N
    ** Of the 7 patients all were in remission beginning on day
1, with 5 in remission as early as 2 hours after dosing- co
    ** The study used a test measuring mood-related symptoms
such as sadness and pessimistic thoughts to get the results
    ** Co says the trial also met its secondary goals, showing a
decline of 24.4 points in mood-related symptoms from baseline at
day 7
    ** Company also reports preliminary results from a Phase 1
trial testing three different doses of the drug in healthy
volunteers; says trial showed safety profile of the drug
    ** Including session's gains, stock up 42.5% from IPO in
June

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))